Boehringer Ingelheim break ground on $217 million Fremont facility
pharmafile | August 1, 2017 | News story | Manufacturing and Production | Boehringer Ingelheim, biotech, drugs, pharma, pharmaceutical
Boehringer Ingelheim announced that it had broken ground on its planned $217 million upgrade and expansion of its existing Fermont manufacturing facility. The investment is expected to create a further 300 jobs to the city of Fremont, just south of San Francisco.
The facility produces biologics and biosimilars, with a focus on oncology, rheumatology and immunology. Should the expansion be carried out as planned, the production capability of the plant will be boosted by a third.
The facility currently covers 300,000 square feet and includes development labs, a pilot plant and large-scale bioreactors. The company had acquired the facility from Amgen, back in 2011, as part of a concerted effort to improve its contract biologics production.
“The Bay Area is the largest biotech cluster in the world. We are happy to have made Fremont our home and are grateful for the support we have received from the community and the State of California,” said Jens Vogel, President and CEO of Boehringer Ingelheim Fremont, Inc. “We have made a commitment to the region and are excited to continue to invest in the Bay Area and expand our workforce to help increase patient access to high-quality medicines.”
For its part of the commitment, the state provided the company with $25.5 million in two separate tax credits from the state – the largest award given to a pharmaceutical company. The facility is one of a global network of such manufacturing plants, that includes further locations in Germany, Austria and China.
Ben Hargreaves
Related Content
Lilly opens fourth US Gateway Labs site
Eli Lilly has opened its newest Lilly Gateway Labs (LGL) site in San Diego, California, …
LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …
Crown Bioscience opens new US model development centre
Crown Bioscience, a US global contract research organisation (CRO) that is part of JSR Life …
